Radiotherapy and bevacizumab for intramedullary and leptomenigeal metastatic glioblastoma: a case report and review of the literature.
Glioblastoma (GBM) developed metastases rarely and the prognosis, in these cases, was very poor. We reported a 30-year patient who, developing intramedullary and leptomeningeal metastases from GBM, underwent palliative spinal radiotherapy (RT) and Bevacizumab.
Department of Radiotherapy Oncology, IRCCS/CROB, Rionero in Vulture (PZ), Italy. albafiorentino@hotmail.it
Alba
A
Fiorentino
Rocchina
R
Caivano
Costanza
C
Chiumento
Mariella
M
Cozzolino
Vincenzo
V
Fusco
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D005909:Glioblastoma / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008297:Male; D008577:Meningeal Neoplasms / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D013120:Spinal Cord Neoplasms / Q000556:secondary / Q000601:surgery / Q000628:therapy*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab